A Proposal for New Evaluation Metrics and Result Visualization Technique for Sentiment Analysis Tasks

Proceedings of: 4th International Conference of the CLEF Initiative (CLEF 2013). 4th International Conference of the CLEF Initiative (CLEF 2013). Valencia, Spain, September 23-26, 2013.In this paper we propound the use of a number of entropybased metrics and a visualization tool for the intrinsic evaluation of Sentiment and Reputation Analysis tasks. We provide a theoretical justification for their use and discuss how they complement other accuracybased metrics. We apply the proposed techniques to the analysis of TASS-SEPLN and RepLab 2012 results and show how the metric is effective for system comparison purposes, for system development and postmortem evaluation.FJVA and JCdA are supported by EU FP7 project LiMoSINe (contract 288024). CPM has been partially supported by the Spanish Government-Comisión Interministerial de Ciencia y Tecnología project TEC2011-26807 for this paper.Publicad

Genealogical data of Boer and Nubian goats in Mexico

The pedigree file of the Boer and Nubian goat breeds in Mexico was constructed using the national database provided by the Asociación Mexicana de Criadores de Ganado Caprino de Registro. Field technicians routinely updated the goat national database by recording information from flocks participating in the performance-recording system. Information on animal identification number, parents, birth date, sex, breed, and farm of origin were used to undertake pedigree analyses using the ENDOG program (version 4.8). This paper presents a pedigree data file, tables and figures of characteristics of pedigree data, pedigree analyses, pedigree integrity, effective population size and genetic conservation index. The data can be used to estimate other population parameters, to monitor the genetic diversity of the Boer and Nubian goat breeds in Mexico, and also to design balanced breeding programs, maintaining genetic variation at reasonable levels and maximizing genetic progress in these populations.202

Osteocondritis disecante de primera cuña en la infancia: presentación de 1 caso

Se presenta un caso de osteocondritis disecante de la primera cuña en la infancia, patología no descrita hasta el momento en la literatura mundial. Se trata de una niña de 11 años que se estudió por dolor de 1 año de evolución y tras llegar al diagnóstico se trató mediante artrodesis de la primera articulación escafocuneana, encontrándose la paciente asintomática tras 10 meses de seguimiento.We report a case of osteochondritis dissecans of the first cuneiform bone in a child. We have not found a similar case in world literature. She is an 11 years old girl with 1 year of pain in her foot. After the diagnosis was made, the treatment was an arthrodesis of the first naviculo-cuneiform joint. The patient is now asympthomatic after 10 months of follow-u

Fracturas de estrés en la infancia

Aportamos 13 casos de fracturas de estrés diagnosticadas en nuestro centro en los últimos 5 años ocurridas en niños entre 4 y 15 años de edad. Encontramos una mayor incidencia en el sexo masculino (9 de los 13 casos), así como un claro predominio de la localización en el tercio proximal de la diáfisis tibial (7 casos), hallazgos que concuerdan con los referidos en la literatura. Uno de los aspectos más interesantes de este tipo de fracturas es su similitud tanto clínica como radiológica con procesos de origen infeccioso y neoplásico, por lo que la realización de un correcto diagnóstico diferencial, apoyado en las radiografías simples, tomografías, gammagrafía, TAC y, más recientemente, RMN, resulta crucial.We present 13 cases of stress fractures in children, collected in our center during the last 5 years. The age of patients ranged from 4 to 15 years old. In agreement with literature, we found a greater incidence on males (9 of 13 cases), and a predominant location on the proximal shaft of the tibia (7 cases). One of the most interesting aspects of this type of fractures is their clinical and radiological similarity with infections and tumors. Therefore, it is essential to achieve a right diagnosis based on standard radiographs, tomography, radionuclide bone scan, CT-scan and, most recently, MRI

Scale free networks from a Hamiltonian dynamics

Contrary to many recent models of growing networks, we present a model with fixed number of nodes and links, where it is introduced a dynamics favoring the formation of links between nodes with degree of connectivity as different as possible. By applying a local rewiring move, the network reaches equilibrium states assuming broad degree distributions, which have a power law form in an intermediate range of the parameters used. Interestingly, in the same range we find non-trivial hierarchical clustering.Comment: 4 pages, revtex4, 5 figures. v2: corrected statements about equilibriu

Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors

Gastrointestinal stromal tumor (GIST) initiation and evolution is commonly framed by KIT/PDGFRA oncogenic activation, and in later stages by the polyclonal expansion of resistant subpopulations harboring KIT secondary mutations after the onset of imatinib resistance. Thus, circulating tumor (ct)DNA determination is expected to be an informative non-invasive dynamic biomarker in GIST patients. We performed amplicon-based next-generation sequencing (NGS) across 60 clinically relevant genes in 37 plasma samples from 18 GIST patients collected prospectively. ctDNA alterations were compared with NGS of matched tumor tissue samples (obtained either simultaneously or at the time of diagnosis) and cross-validated with droplet digital PCR (ddPCR). We were able to identify cfDNA mutations in five out of 18 patients had detectable in at least one timepoint. Overall, NGS sensitivity for detection of cell-free (cf)DNA mutations in plasma was 28.6%, showing high concordance with ddPCR confirmation. We found that GIST had relatively low ctDNA shedding, and mutations were at low allele frequencies. ctDNA was detected only in GIST patients with advanced disease after imatinib failure, predicting tumor dynamics in serial monitoring. KIT secondary mutations were the only mechanism of resistance found across 10 imatinib-resistant GIST patients progressing to sunitinib or regorafenib. ctDNA evaluation with amplicon-based NGS detects KIT primary and secondary mutations in metastatic GIST patients, particularly after imatinib progression. GIST exhibits low ctDNA shedding, but ctDNA monitoring, when positive, reflects tumor dynamics

Nivolumab and sunitinib combination in advanced soft tissue sarcomas : A multicenter, single-arm, phase Ib/II trial

Sarcomas exhibit low expression of factors related to immune response, which could explain the modest activity of PD-1 inhibitors. A potential strategy to convert a cold into an inflamed microenvironment lies on a combination therapy. As tumor angiogenesis promotes immunosuppression, we designed a phase Ib/II trial to test the double inhibition of angiogenesis (sunitinib) and PD-1/PD-L1 axis (nivolumab). This single-arm, phase Ib/II trial enrolled adult patients with selected subtypes of sarcoma. Phase Ib established two dose levels: level 0 with sunitinib 37.5 mg daily from day 1, plus nivolumab 3 mg/kg intravenously on day 15, and then every 2 weeks; and level-1 with sunitinib 37.5 mg on the first 14 days (induction) and then 25 mg per day plus nivolumab on the same schedule. The primary endpoint was to determine the recommended dose for phase II (phase I) and the 6-month progression-free survival rate, according to Response Evaluation Criteria in Solid Tumors 1.1 (phase II). From May 2017 to April 2019, 68 patients were enrolled: 16 in phase Ib and 52 in phase II. The recommended dose of sunitinib for phase II was 37.5 mg as induction and then 25 mg in combination with nivolumab. After a median follow-up of 17 months (4-26), the 6-month progression-free survival rate was 48% (95% CI 41% to 55%). The most common grade 3-4 adverse events included transaminitis (17.3%) and neutropenia (11.5%). Sunitinib plus nivolumab is an active scheme with manageable toxicity in the treatment of selected patients with advanced soft tissue sarcoma, with almost half of patients free of progression at 6 months

Study of dielectron production in C+C collisions at 1 AGeV

The emission of e+e- pairs from C+C collisions at an incident energy of 1 GeV per nucleon has been investigated. The measured production probabilities, spanning from the pi0-Dalitz to the rho/omega! invariant-mass region, display a strong excess above the cocktail of standard hadronic sources. The bombarding-energy dependence of this excess is found to scale like pion production, rather than like eta production. The data are in good agreement with results obtained in the former DLS experiment.Comment: submitted to Physics Letters